Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Citius Oncology, Inc.NASDAQ: CTOR
Cash & Equivalents · Q2 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 2350466.1% from a year ago
Cash & equivalents stood at $2.63M at the end of Q2 FY2026, up 2350466.1% from a year earlier and down 63.9% from the prior quarter.
Context
- Cash & equivalents amounted to 2.6% of total assets at the end of Q2 FY2026, up 2.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +2350466.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 3.92M USD
- Year-over-year change
- +3504282.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 3.92M | +3504282.1% |
| FY2024 | 2024-09-30 | 112 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Cash & Equivalents vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 cash & equivalents of $2.63M is the lowest of the 10 companies compared; the peer median is $39.57M.
- Its year-over-year change of +2350466.1% is the highest of 10, against a peer median of +14.8%.
- Cash & equivalents amounts to 2.6% of total assets for CTOR, versus a peer median of 33.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $169.87M | +239.4% | +90.1% | 33.5% | |
| Mar 2026 | $58.22M | +27.0% | +23.3% | 86.6% | |
| Mar 2026 | $56.13M | +14.8% | -28.3% | 95.1% | |
| Mar 2026 | $41.01M | +151.4% | +46.8% | 47.3% | |
| Mar 2026 | $39.57M | -11.9% | -8.7% | 13.9% | |
| Mar 2026 | $29.83M | -49.3% | -34.5% | 25.4% | |
| Mar 2026 | $12.49M | -36.1% | -4.0% | 18.9% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.13M | +109.1% | -13.7% | 91.3% |
| Mar 2026 | $3.35M | -42.2% | +31.4% | 1.1% | |
CTORCitius Oncology, Inc. | Mar 2026 | $2.63M | +2350466.1% | — | 2.6% |
| Peer median (excluding CTOR) | $39.57M | +14.8% | -4.0% | 33.5% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.